Product Introduction

OBEDA 1mg is a prescription injectable medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The supplied packaging identifies it as a prefilled injection pen containing 4 mg of semaglutide in 3 mL of solution, at a concentration of approximately 1.34 mg/mL.

Semaglutide acts on GLP-1 receptors involved in blood glucose regulation, insulin secretion, appetite and gastrointestinal motility. Depending on the specific product's approved indication, it may be prescribed for managing type 2 diabetes and related metabolic needs. Do not assume that every semaglutide product is approved for weight management; the appropriate indication depends on the product's authorization and the treating specialist's assessment.

The OBEDA package states that the pen delivers doses in 1 mg increments only and that dosage must be as directed by a doctor. It is intended for subcutaneous administration and is marked for prescription-only sale on the prescription of an endocrinologist or internal medicine specialist.

Important: This medicine must not be self-prescribed or used solely for cosmetic weight loss. Confirm the approved indication, dosing schedule and suitability with the prescribing specialist before dispensing or use.

Uses

• Type 2 diabetes management: Semaglutide is used in approved formulations to help improve glycaemic control in adults with type 2 diabetes.

• Blood glucose regulation: Helps support glucose-dependent insulin secretion and reduce inappropriate glucagon secretion.

• Metabolic management: May be considered by a specialist as part of a comprehensive treatment plan, depending on the product's approved indications.

• Weight management: Semaglutide has weight-management indications in certain specifically approved products and doses. Do not advertise OBEDA for this purpose unless its applicable Indian product authorization supports that claim.

It is not intended for treating type 1 diabetes or diabetic ketoacidosis.

Key Ingredients & Full Ingredients

Active ingredient

• Semaglutide: 1.34 mg per mL.

• Total semaglutide content: 4 mg in 3 mL.

Other ingredients listed on the packaging

• Disodium phosphate dihydrate

• Propylene glycol: 14.0 mg per mL

• Phenol: 5.50 mg per mL

• Water for injection

• Hydrochloric acid or sodium hydroxide may be added to adjust pH.

Label transcription note: The quantity printed for disodium phosphate dihydrate is not sufficiently legible in the supplied image. Please verify it against the original pack or approved package insert before publishing a numerical quantity.

Benefits

• Helps improve blood glucose control when used for an approved indication.

• Stimulates insulin secretion in a glucose-dependent manner.

• Helps reduce glucagon secretion when blood glucose is elevated.

• May slow gastric emptying and influence appetite.

• May support weight reduction with appropriately approved semaglutide treatment, alongside dietary and lifestyle measures.

• Prefilled pen format allows administration according to the prescribed regimen.

• Contains a clearly labelled 4 mg total quantity in a 3 mL solution.

• The package specifies 1 mg dose increments, supporting clearly defined prescribed doses.

Individual results vary. Benefits depend on the indication, prescribed regimen, adherence and other medical factors.

Side Effects

Common or relatively frequent side effects

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal discomfort or pain

• Bloating, indigestion or reduced appetite

These effects may be more noticeable when treatment begins or after a prescribed dose increase.

Serious side effects requiring prompt medical attention

• Acute pancreatitis: Persistent, severe abdominal pain, sometimes radiating to the back, with or without vomiting.

• Gallbladder problems: Severe upper abdominal pain, fever or yellowing of the skin or eyes.

• Dehydration and kidney injury: Persistent vomiting or diarrhoea, reduced urination or marked dizziness.

• Hypoglycaemia: Low blood glucose, especially when used with insulin or sulfonylureas.

• Allergic reactions: Facial or throat swelling, difficulty breathing or a widespread severe rash.

• Worsening diabetic retinopathy: Changes in vision, particularly in susceptible patients experiencing rapid improvement in blood glucose.

• Severe gastrointestinal symptoms: Persistent symptoms or inability to keep fluids down.

Seek emergency medical care for breathing difficulty, severe allergic reactions or symptoms suggestive of pancreatitis.

Product Form

• Dosage form: Solution for injection

• Delivery system: Prefilled pen

• Route: Subcutaneous injection

• Strength: 4 mg/3 mL (approximately 1.34 mg/mL)

• Labelled dose: OBEDA 1 mg; pen delivers doses in 1 mg increments only

• Pack size: 1 sterile prefilled pen

• Prescription status: Prescription-only; specialist prescription required as stated on the package

How to Use

1. Obtain a valid prescription. Use only under the supervision of the prescribing endocrinologist or internal medicine specialist.

2. Verify the product. Check the name, strength, expiry date, packaging integrity and solution appearance. Do not use a damaged pen or a pen with a broken seal before first use.

3. Check the instructions. Read the enclosed product literature and have a healthcare professional demonstrate pen use before the first injection.

4. Administer subcutaneously. The injection is given under the skin, commonly in the abdomen, thigh or upper arm, as instructed by the healthcare professional. Do not inject into a vein or muscle.

5. Follow the prescribed schedule. Do not choose a dose, change the frequency or increase the dose independently. The package specifies that this pen delivers 1 mg increments only.

6. Use safely. Follow the pen's instructions for compatible needles, injection technique, needle disposal and prevention of contamination. Do not share the pen with another person.

7. Store correctly. Refrigerate at 2–8°C before first use; do not freeze. The supplied pack states that after first use the pen can be stored for 56 days at no more than 30°C or refrigerated at 2–8°C. Follow the enclosed leaflet for any additional handling instructions.

If a dose is missed, consult the product leaflet or prescribing clinician for product-specific instructions. Do not double the next dose.

How It Works

Semaglutide mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone.

• Glucose-dependent insulin secretion: Enhances insulin release from pancreatic beta cells when blood glucose is elevated.

• Glucagon regulation: Reduces inappropriate glucagon secretion, helping limit excess glucose production by the liver.

• Gastric emptying: Can slow the movement of food from the stomach, particularly during early treatment.

• Appetite regulation: Acts on pathways involved in appetite and satiety, which can contribute to reduced food intake.

Together, these actions can improve blood glucose control. The extent of weight change and other clinical outcomes varies by individual and treatment regimen.

3. Medical & Safety Information

Safety Advice

Prescription-only medicine. The supplied packaging specifically restricts retail sale to prescriptions from an endocrinologist or internal medicine specialist.

• Pregnancy: Semaglutide is generally not recommended during pregnancy. Anyone who is pregnant, planning pregnancy or suspects pregnancy should contact their specialist before use. Semaglutide is typically discontinued at least two months before a planned pregnancy under prescribing guidance.

• Breastfeeding: Safety information is limited and product-specific. Consult the prescribing specialist before use.

• Alcohol: Alcohol may affect blood glucose and increase the risk of hypoglycaemia when semaglutide is combined with insulin or sulfonylureas. It may also worsen gastrointestinal symptoms. Discuss alcohol consumption with the treating clinician.

• Driving: Semaglutide alone does not usually impair driving. However, hypoglycaemia, particularly when combined with certain diabetes medicines, can impair concentration and reaction time. Do not drive if dizzy, confused or experiencing low blood glucose.

• Kidney conditions: Dehydration from vomiting or diarrhoea can worsen kidney function. Patients with kidney disease should receive appropriate monitoring.

• Liver conditions: Inform the prescribing clinician about any liver disease; suitability should be assessed individually.

• Pancreatitis: Tell the clinician about previous or current pancreatitis. Severe persistent abdominal pain requires urgent assessment.

• Gallbladder disease: Report a history of gallstones or gallbladder inflammation.

• Diabetic eye disease: Patients with diabetic retinopathy should discuss monitoring, particularly if blood glucose is expected to improve rapidly.

• Thyroid tumour history: Discuss any personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). Contraindications and warnings must be checked against the locally approved product information.

• Other diabetes medicines: Insulin and sulfonylureas may require clinician-directed dose adjustments to reduce hypoglycaemia risk.

Do not start, stop or change any prescribed medicine without medical advice.

Quick Tips

• Keep the pen refrigerated at 2–8°C before first use and never freeze it.

• Follow the package's 56-day in-use storage limit and maximum temperature of 30°C.

• Check the expiry date and solution condition before each use.

• Follow the approved pen instructions for needle attachment, injection and disposal.

• Never share the pen, even if the needle is changed.

• Maintain regular meals, adequate hydration and any recommended blood glucose monitoring.

• Keep follow-up appointments so the clinician can assess efficacy, tolerability and other medicines.

• Contact a healthcare professional if gastrointestinal symptoms are persistent or severe.

Fact Box

Interaction with Drugs

Semaglutide can affect blood glucose and gastric emptying, so the prescribing clinician should review all medicines, including non-prescription products.

Important: This is a general interaction overview, not a complete product-specific interaction list. The prescriber and pharmacist should check the patient's complete medication history and the approved package insert.

4. Business Details

Manufacturer, Importer, and Marketer

The following details are transcribed from the supplied packaging. No importer or separate marketer is identified in the visible images.

Manufactured in India by:

Manufacturing licence number:

Other packaging details:

• Brand: OBEDA

• Pack: Sterile, one prefilled pen

• Total contents: 4 mg semaglutide in 3 mL

• Prescription warning: To be sold by retail on the prescription of an endocrinologist or internal medicine specialist only.

• Barcode digits visible on the pack: 8901148277762

Importer: Not specified on the supplied images.

Separate marketer: Not specified on the supplied images.

Do not add a different marketer, importer, address, certification or regulatory claim without verifying it against the complete product packaging and official records.

5. FAQs

Q1. What is OBEDA 1mg Semaglutide Injection used for?

OBEDA contains semaglutide, a GLP-1 receptor agonist. Semaglutide is used in approved formulations to help manage type 2 diabetes. The specific approved indication for OBEDA should be confirmed before prescribing or dispensing.

Q2. What is the strength of the OBEDA prefilled pen?

The supplied packaging states that the pen contains 4 mg of semaglutide in 3 mL of solution, with a concentration of approximately 1.34 mg/mL. The pen delivers doses in 1 mg increments only.

Q3. Can OBEDA be used for weight loss?

Semaglutide can support weight management in certain specifically approved products and regimens. However, weight loss should not be assumed to be an approved indication for OBEDA. Consult a qualified specialist and verify the product's authorization.

Q4. How should the OBEDA pen be stored?

According to the supplied pack, refrigerate at 2–8°C before first use and do not freeze. After first use, the pen may be stored for up to 56 days at temperatures not exceeding 30°C or refrigerated at 2–8°C. Follow the enclosed leaflet.

Q5. What are the common side effects of semaglutide?

Common side effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Seek urgent medical attention for severe persistent abdominal pain, a serious allergic reaction or symptoms of severe dehydration.